Stocks · News reference
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.
Evercore ISI Group Initiates Coverage On First Tracks with Outperform Rating, Announces Price Target of $65
Evercore ISI Group initiates coverage on First Tracks (NASDAQ:TRAX) with a Outperform rating and announces Price Target of $65.
Guggenheim Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $100
Guggenheim analyst Yatin Suneja initiates coverage on First Tracks (NASDAQ:TRAX) with a Buy rating and announces Price Target of $100.